Literature DB >> 9855063

5T4 oncofetal antigen in gastric carcinoma and its clinical significance.

T Starzynska1, A Wiechowska-Kozlowska, K Marlicz, M Bromley, S A Roberts, M Lawniczak, B Kolodziej, A Zyluk, P L Stern.   

Abstract

OBJECTIVE: To evaluate the role of 5T4 antigen in gastric cancer progression and prognosis.
DESIGN: A prospective study of 5T4 antigen expression in primary, secondary and recurrent gastric carcinoma, the relationship to selected prognostic parameters and the course of disease. PATIENTS: Eighty six patients operated on for gastric cancer. TISSUE: One hundred and twenty two gastric tumours were studied, including 86 primary carcinomas, 32 coexisting lymph node metastases and four recurrent carcinomas.
METHODS: Immunohistochemistry using 5T4 monoclonal antibody on frozen sections.
RESULTS: The 5T4 antigen was detected in 41% of primary gastric tumours including early gastric cancer. A strong relationship was found between 5T4 positivity and tumour histology. Thus, 52% of gastric carcinomas of intestinal type expressed 5T4 antigen compared with 28% of the diffuse type (P = 0.028). Among 16 sets of primary gastric carcinomas and regional lymph node metastases, coordinate 5T4 expression was seen in 14 cases; the other two showed acquisition of positivity on metastatic tumour cells (carcinomas of diffuse type). 5T4 antigen was detected more frequently in carcinomas with p53 accumulation compared with those with undetectable p53 levels (P = 0.015). The presence of 5T4 in cancer cells was correlated with poor short-term prognosis (24% vs 49% of 2 year survival for 5T4 positive and negative tumours respectively, P = 0.024). The effect on survival was evident in the p53 negative group, with patients 5T4 positive showing worse survival (28% vs 60% in 2 years).
CONCLUSIONS: Our results suggest that the assessment of 5T4 expression in gastric carcinoma can be helpful in identifying patients with poor short-term prognosis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9855063     DOI: 10.1097/00042737-199806000-00008

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  15 in total

1.  Identification of a major histocompatibility complex class I-restricted T-cell epitope in the tumour-associated antigen, 5T4.

Authors:  Irina Redchenko; Richard Harrop; Matthew G Ryan; Robert E Hawkins; Miles W Carroll
Journal:  Immunology       Date:  2006-05       Impact factor: 7.397

2.  Glycosylation and epitope mapping of the 5T4 glycoprotein oncofoetal antigen.

Authors:  David M Shaw; Andrew M Woods; Kevin A Myers; Caroline Westwater; Veena Rahi-Saund; Michael J Davies; David V Renouf; Elizabeth F Hounsell; Peter L Stern
Journal:  Biochem J       Date:  2002-04-01       Impact factor: 3.857

3.  Characterization of the murine 5T4 oncofoetal antigen: a target for immunotherapy in cancer.

Authors:  Andrew M Woods; Who W Wang; David M Shaw; Christopher M Ward; Miles W Carroll; Buddug R Rees; Peter L Stern
Journal:  Biochem J       Date:  2002-08-15       Impact factor: 3.857

4.  Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients.

Authors:  Andrea Pellagatti; Martin Jädersten; Ann-Mari Forsblom; Helen Cattan; Birger Christensson; Emma K Emanuelsson; Mats Merup; Lars Nilsson; Jan Samuelsson; Birgitta Sander; James S Wainscoat; Jacqueline Boultwood; Eva Hellström-Lindberg
Journal:  Proc Natl Acad Sci U S A       Date:  2007-06-18       Impact factor: 11.205

Review 5.  Development of modified vaccinia Ankara-5T4 as specific immunotherapy for advanced human cancer.

Authors:  Scott S Tykodi; John A Thompson
Journal:  Expert Opin Biol Ther       Date:  2008-12       Impact factor: 4.388

6.  CXCR4 mediated chemotaxis is regulated by 5T4 oncofetal glycoprotein in mouse embryonic cells.

Authors:  Thomas D Southgate; Owen J McGinn; Fernanda V Castro; Andrzej J Rutkowski; Mariam Al-Muftah; Georgi Marinov; Graeme J Smethurst; David Shaw; Christopher M Ward; Crispin J Miller; Peter L Stern
Journal:  PLoS One       Date:  2010-04-01       Impact factor: 3.240

7.  Trophoblast glycoprotein is a marker for efficient sorting of ventral mesencephalic dopaminergic precursors derived from human pluripotent stem cells.

Authors:  Jeong-Eun Yoo; Dongjin R Lee; Sanghyun Park; Hye-Rim Shin; Kun Gu Lee; Dae-Sung Kim; Mi-Young Jo; Jang-Hyeon Eom; Myung Soo Cho; Dong-Youn Hwang; Dong-Wook Kim
Journal:  NPJ Parkinsons Dis       Date:  2021-07-19

8.  Loss of function of e-cadherin in embryonic stem cells and the relevance to models of tumorigenesis.

Authors:  Lisa Mohamet; Kate Hawkins; Christopher M Ward
Journal:  J Oncol       Date:  2010-12-09       Impact factor: 4.375

9.  Therapy of human non-small-cell lung carcinoma using antibody targeting of a modified superantigen.

Authors:  G Forsberg; L Ohlsson; T Brodin; P Björk; P A Lando; D Shaw; P L Stern; M Dohlsten
Journal:  Br J Cancer       Date:  2001-07-06       Impact factor: 7.640

10.  Identification of Pre- and Post-Treatment Markers, Clinical, and Laboratory Parameters Associated with Outcome in Renal Cancer Patients Treated with MVA-5T4.

Authors:  Rabih Said; Robert J Amato
Journal:  Front Oncol       Date:  2013-07-15       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.